• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[关于阿那白滞素用于治疗新型冠状病毒肺炎继发急性呼吸窘迫综合征的建议]

[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].

作者信息

Muñoz-Jiménez Alejandro, Rubio-Romero Esteban, Marenco de la Fuente José Luis

机构信息

Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, España.

Servicio de Reumatología, Hospital Universitario Virgen de Valme , Sevilla, España.

出版信息

Reumatol Clin. 2021 Jun-Jul;17(6):309-312. doi: 10.1016/j.reuma.2020.04.009. Epub 2020 Apr 27.

DOI:10.1016/j.reuma.2020.04.009
PMID:38620280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7183956/
Abstract

The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ß. We propose its use in controlling ARDS secondary to COVID-19 infection.

摘要

严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即新冠病毒）感染的结果从根本上影响肺脏，导致急性呼吸窘迫综合征（ARDS）。这一过程呈现出炎症特征，涉及由NLRP3炎性小体引发的细胞因子风暴，而细胞因子风暴是肺泡破坏的主要因素。白细胞介素-1β（IL-1β）在这一过程中被触发的细胞因子中尤为突出。阿那白滞素是一种强效生物药物，能够阻断这种IL-1β。我们建议将其用于控制新冠病毒感染继发的ARDS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e27/7183956/10bbd87dfe40/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e27/7183956/7e05ee193f2f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e27/7183956/10bbd87dfe40/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e27/7183956/7e05ee193f2f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e27/7183956/10bbd87dfe40/gr2_lrg.jpg

相似文献

1
[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].[关于阿那白滞素用于治疗新型冠状病毒肺炎继发急性呼吸窘迫综合征的建议]
Reumatol Clin. 2021 Jun-Jul;17(6):309-312. doi: 10.1016/j.reuma.2020.04.009. Epub 2020 Apr 27.
2
[Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].[关于阿那白滞素用于新型冠状病毒肺炎继发急性呼吸窘迫综合征的建议]
Reumatol Clin (Engl Ed). 2021 Jun-Jul;17(6):309-312. doi: 10.1016/j.reuma.2020.04.009. Epub 2020 Apr 27.
3
Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.COVID-19 相关急性呼吸窘迫综合征和肺外多器官功能障碍患者炎症细胞因子风暴中的特定细胞因子。
Virol J. 2021 Jun 4;18(1):117. doi: 10.1186/s12985-021-01588-y.
4
Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.新型冠状病毒-19（SARS-CoV-2）通过白细胞介素-1（IL-1）引起细胞因子风暴导致 COVID-19 的急性重症肺部炎症：一种有前途的抑制策略。
J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):1971-1975. doi: 10.23812/20-1-E.
5
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).炎症细胞因子（白细胞介素-1 和白细胞介素-6）在 COVID-19（轻症、重症和危重症）不同阶段作为潜在生物标志物的作用。
J Interferon Cytokine Res. 2023 Apr;43(4):147-163. doi: 10.1089/jir.2022.0185.
6
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
7
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.固有受体激活模式涉及 COVID-19、ALI/ARDS 和脓毒症细胞因子风暴中的 TLR 和 NLR 协同作用：综述和模型制作新的预测和治疗建议。
Int J Mol Sci. 2021 Feb 20;22(4):2108. doi: 10.3390/ijms22042108.
8
Anakinra reduces lung inflammation in experimental acute lung injury.阿那白滞素可减轻实验性急性肺损伤中的肺部炎症。
Immun Inflamm Dis. 2022 Feb;10(2):123-129. doi: 10.1002/iid3.548. Epub 2021 Dec 9.
9
COVID-19 infection: an overview on cytokine storm and related interventions.COVID-19 感染：细胞因子风暴及相关干预措施概述。
Virol J. 2022 May 26;19(1):92. doi: 10.1186/s12985-022-01814-1.
10
A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug.深入探究地塞米松与SARS-CoV-2引发的细胞因子风暴：对首款挽救生命的COVID-19药物的计算机模拟见解
Antibiotics (Basel). 2021 Dec 8;10(12):1507. doi: 10.3390/antibiotics10121507.

引用本文的文献

1
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.COVID-19 治疗的免疫调节剂：可能的作用机制和免疫病理学特征。
Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11.
2
[COVID-19 pneumonia].[新型冠状病毒肺炎]
Gastroenterologe. 2020;15(6):457-470. doi: 10.1007/s11377-020-00488-x. Epub 2020 Nov 11.
3
Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).治疗 SARS-CoV-2 感染（COVID-19）期间开具的药物的重要药物遗传学信息。

本文引用的文献

1
Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1.比较 COVID-19 和 H1N1 导致的 ARDS 住院患者。
Chest. 2020 Jul;158(1):195-205. doi: 10.1016/j.chest.2020.03.032. Epub 2020 Mar 26.
2
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature.卡那单抗治疗家族性地中海热的疗效、安全性及耐受性：文献系统评价
J Inflamm Res. 2020 Mar 9;13:141-149. doi: 10.2147/JIR.S206204. eCollection 2020.
3
The Basic Science and Molecular Mechanisms of Lung Injury and Acute Respiratory Distress Syndrome.
Clin Transl Sci. 2020 Nov;13(6):1023-1033. doi: 10.1111/cts.12866. Epub 2020 Sep 16.
4
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.高剂量皮下注射阿那白滞素治疗重症 COVID-19 患者细胞因子风暴综合征继发急性呼吸窘迫综合征。
J Autoimmun. 2020 Dec;115:102537. doi: 10.1016/j.jaut.2020.102537. Epub 2020 Aug 20.
5
[COVID-19 pneumonia].[新型冠状病毒肺炎]
Internist (Berl). 2020 Aug;61(8):793-803. doi: 10.1007/s00108-020-00854-5.
肺损伤与急性呼吸窘迫综合征的基础科学及分子机制
Int Anesthesiol Clin. 2018 Winter;56(1):1-25. doi: 10.1097/AIA.0000000000000177.
4
Melatonin as an Anti-Inflammatory Agent Modulating Inflammasome Activation.褪黑素作为一种调节炎性小体激活的抗炎剂。
Int J Endocrinol. 2017;2017:1835195. doi: 10.1155/2017/1835195. Epub 2017 Oct 1.
5
The acute respiratory distress syndrome: from mechanism to translation.急性呼吸窘迫综合征：从机制到转化
J Immunol. 2015 Feb 1;194(3):855-60. doi: 10.4049/jimmunol.1402513.
6
Critical role for the NLRP3 inflammasome during acute lung injury.NLRP3 炎性小体在急性肺损伤中的关键作用。
J Immunol. 2014 Jun 15;192(12):5974-83. doi: 10.4049/jimmunol.1400368. Epub 2014 May 2.
7
The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury.NLRP3 炎性体在 LPS/机械通气急性肺损伤致低氧血症发生中起重要作用。
Am J Respir Cell Mol Biol. 2014 Feb;50(2):270-80. doi: 10.1165/rcmb.2013-0087OC.
8
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.在广泛的疾病中通过阻断白细胞介素-1来治疗炎症。
Nat Rev Drug Discov. 2012 Aug;11(8):633-52. doi: 10.1038/nrd3800.
9
Sensing and reacting to microbes through the inflammasomes.通过炎症小体感知和应对微生物。
Nat Immunol. 2012 Mar 19;13(4):325-32. doi: 10.1038/ni.2231.
10
NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways.NLRP3（NALP3，冷吡啉）通过炎性小体依赖性和非依赖性途径促进体内半胱天冬酶-1激活、坏死和高迁移率族蛋白B1释放。
J Immunol. 2009 Aug 1;183(3):2008-15. doi: 10.4049/jimmunol.0900138. Epub 2009 Jul 8.